Vitala's mission focuses on pioneering human-centric tools and strategies, diverging from traditional animal models. They aim to create in-vivo-like in vitro assays, particularly emphasizing Oncology and Metabolic diseases. The proposed Organ-on-a-Chip (OoC) model promises a more accurate representation of human biology than standard cell cultures or animal models. Preliminary results indicate the potential to produce over 30 OoCs from a single mouse liver, offering an ethical and efficient alternative to animal testing.
This revolutionary technology allows simultaneous testing of multiple substances on diverse organoids, expediting research outcomes. The controlled biological systems reduce costs and complexities, promising cost-effective and time-efficient experimentation. While liver-related metabolic changes take center stage, the tools' versatility extends to various organs and diseases.
Vitala's OoC platform is anticipated to transform health technology, improving drug testing, disease modeling, and toxicology research. It aims to boost productivity in discovery programs, mitigate drug failure risks in clinical trials, and potentially enhance the drug discovery and preclinical services market. Disease-on-chip platforms could address unmet medical needs, especially in diseases lacking effective treatments.
The envisioned metabolic imaging strategies are poised to deepen understanding of disease processes, aiding in prediction, prevention, and treatment. Personalized responses to treatments, derived from patient-specific cells, can predict drug responses and toxicity, reducing adverse effects in clinical trials.
To gain regulatory confidence, robust processes and recognition from agencies like the US FDA and EU EMA for New Approach Methods (NAMs) are critical. This shift towards socially accepted and sustainable non-animal biomedical research aligns with global environmental concerns.
Building societal acceptance involves extensive stakeholder engagement and workshops, ensuring the long-term sustainability of these approaches. This approach aims to build trust, mitigate risks, and regulate impacts within the EU region.
Contributing to 'Good health and high-quality accessible health care,' Vitala's initiative aligns with the health cluster's strategic plan. This international collaboration emphasizes the value of global cooperation, enhancing the EU's leadership in health technology development.
